NIBIT, the Italian Network for Cancer Biotherapy, is a non-profit organization representing more than 150 official members from over 40 Italian academic, regulatory and industrial groups/organizations. The Network was formed in 2014 to create a cooperative network that would group and coordinate the activities of the various groups that are working on cancer biotherapy in Italy, given the high number of studies regarding the use of innovative approaches in oncology, and in consideration of the increasing number of institutions and professionals involved.
NIBIT is a member of the World Immunotherapy Council, an international forum to facilitate high-level scientific cooperation in the field of cancer immunology and immunotherapy. Cancer Immunology Immunotherapy is the official scientific journal of NIBIT.
The main activities are:
To promote and enhance the scientific and operational interactions among professionals from academia, the biotech/pharmaceutical industry, and regulatory agencies;
To promote initiatives to inform patients on cancer bioimmunotherapy and the clinical trials currently available;
To train physicians about the potential and limits of cancer bio-immunotherapy, and the available clinical trials:
To develop innovative multi-center cancer bio-immunotherapy clinical trials at the national level.
Primary educational and scientific events:
National Masters in Immuno-oncology;
Regional courses on cancer bio-immunotherapy;
"Cancer Bio-Immunotherapy in Siena - the NIBIT Meeting" annual international meeting.
A foundation called “Fondazione NIBIT” was established on the initiative of "NIBIT" in 2012, and aims to carry out scientific and research activities in the biomedical oncological sector, with particular but not exclusive regard to applied research in the pre-clinical and clinical fields in cancer biotherapy. The president of the NIBIT Foundation is Dr. Michele Maio, head of the Oncological Immunotherapy Unit at the Siena University Hospital.